Fibrinogen polymorphisms and disease

European Heart Journal

Volumn 22, Issue 24, 2001, Pages 2224-2226

  Laffan, M A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

DISEASE ASSOCIATION; DNA POLYMORPHISM; EDITORIAL; FIBRINOGEN BLOOD LEVEL; GENETIC ANALYSIS; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; PREDICTION; PRIORITY JOURNAL; VEIN THROMBOSIS;

EPIDEMIOLOGIC STUDIES; FIBRINOGEN; HUMANS; MYOCARDIAL ISCHEMIA; POLYMORPHISM, GENETIC;

EID: 0035658214     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2833     Document Type: Editorial

References (24)

1. Mutation in the promoter region of the β-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis
2. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
3. A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study
4. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the cardiovascular health study
5. European Atherosclerosis Research Study: Genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction
6. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: The Caerphilly and Speedwell studies
7. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
8. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS)
9. Epidemiological evidence for inflammation in cardiovascular disease
10. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies
11. Fibrinogen deficiency is compatible with fhe development of atherosclerosis in mice
12. Why atherosclerotic vessels narrow: The fibrin hypothesis
13. Lowering fibrinogen levels: Clinical update
14. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study
15. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration
16. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men
17. Genetic factors determining thrombosis and fibrinolysis
18. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
19. Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease
20. - 455G/A polymorphism of the beta-fibrinogen gene associated with the progression of coronary atherosclerosis in symptomatic men: Proposed role for an acute-phase reaction pattern of fibrinogen
21. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients
22. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study
23. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
24. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease